Advertisement
Screener

Gyre Therapeutics, Inc. (GYRE) Interest Expense, Related Party

1.5 / 5 stars · 17/57 Roast Me

Gyre Therapeutics, Inc. Interest Expense, Related Party

Gyre Therapeutics, Inc. (GYRE) reported Interest Expense, Related Party of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-08.

Discontinued › Expense Statement › Interest Expense

us-gaap:InterestExpenseRelatedParty · last filed 2017-03-08

  • Gyre Therapeutics, Inc. interest expense, related party for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
  • Gyre Therapeutics, Inc. interest expense, related party for the quarter ending 2016-09-30 was $0.00.
  • Gyre Therapeutics, Inc. interest expense, related party for the quarter ending 2016-06-30 was $0.00.
  • Gyre Therapeutics, Inc. interest expense, related party for the quarter ending 2016-03-31 was $0.00.
  • Gyre Therapeutics, Inc. interest expense, related party for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
  • Gyre Therapeutics, Inc. interest expense, related party for fiscal 2015 was $1.50M.
Period endInterest Expense, Related Party 3 monthInterest Expense, Related Party 3 month as first filedInterest Expense, Related Party 6 monthInterest Expense, Related Party 6 month as first filedInterest Expense, Related Party 9 monthInterest Expense, Related Party 9 month as first filedInterest Expense, Related Party 12 monthInterest Expense, Related Party 12 month as first filed
2016-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08
$0.00
derived: sum of 2 quarters · filed 2017-03-08
$0.00
derived: sum of 3 quarters · filed 2017-03-08
$0.00
10-K · filed 2017-03-08
2016-09-30$0.00
10-Q · filed 2016-11-03
$0.00
derived: sum of 2 quarters · filed 2016-11-03
$0.00
10-Q · filed 2016-11-03
$1.40M
derived: sum of 4 quarters · filed 2017-03-08
2016-06-30$0.00
10-Q · filed 2016-08-04
$0.00
10-Q · filed 2016-08-04
$1.40M
derived: sum of 3 quarters · filed 2017-03-08
$1.40M
derived: sum of 4 quarters · filed 2017-03-08
2016-03-31$0.00
10-Q · filed 2016-05-05
$1.40M
derived: sum of 2 quarters · filed 2017-03-08
$1.40M
derived: sum of 3 quarters · filed 2017-03-08
$1.40M
derived: sum of 4 quarters · filed 2017-03-08
2015-12-31$1.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08
$1.40M
derived: sum of 2 quarters · filed 2017-03-08
$1.40M
derived: sum of 3 quarters · filed 2017-03-08
$1.50M
10-K · filed 2017-03-08
$100.00K
10-K · filed 2016-03-09
2015-09-30$0.00
10-Q · filed 2016-11-03
$39.00M
10-Q · filed 2015-11-05
$0.00
derived: sum of 2 quarters · filed 2016-11-03
$100.00K
10-Q · filed 2016-11-03
$96.00M
10-Q · filed 2015-11-05
2015-06-30$0.00
10-Q · filed 2016-08-04
$39.00K
8-K/A · filed 2015-10-23
$0.00
10-Q · filed 2016-08-04
$39.00K
8-K/A · filed 2015-10-23
2015-03-31$0.00
10-Q · filed 2016-05-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
GERON CORP (GERN)United States$0.803B-12.14
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
Olema Pharmaceuticals, Inc. (OLMA)United States$0.790B-5.35
Wave Life Sciences, Inc. (WVE)$0.780B-5.56
ARDELYX, INC. (ARDX)United States$0.857B-22.86
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78